Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia

  • STATUS
    Not Recruiting
  • End date
    Mar 31, 2025
  • participants needed
    45
  • sponsor
    Institute of Hematology & Blood Diseases Hospital
Updated on 14 September 2022

Summary

This is a phase 2, single-center, single-arm, open-label trial. Simon's two-stage design is performed to evaluate the efficacy of low-dose Decitabine in refractory aplastic anemia.

Details
Condition Refractory Aplastic Anemia
Treatment Decitabine
Clinical Study IdentifierNCT04854889
SponsorInstitute of Hematology & Blood Diseases Hospital
Last Modified on14 September 2022

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note